Risk factors for severe infections in secondary immunodeficiency: a retrospective US administrative claims study in patients with hematological malignancies

Leuk Lymphoma. 2022 Jan;63(1):64-73. doi: 10.1080/10428194.2021.1992761. Epub 2021 Oct 26.

Abstract

Real-world data are lacking to identify patients with secondary immunodeficiency (SID) who may benefit most from anti-infective interventions. This retrospective analysis used the IQVIA PharMetrics® Plus database to assess baseline characteristics associated with risk of severe infections post-SID diagnosis in patients with hematological malignancies. In 4066 patients included, the mean number of any and severe infections per patient in the one-year pre-SID diagnosis period was 9.5 and 0.7, respectively. Post-SID diagnosis, the mean annualized number of any and severe infections was 19.1 and 1.5, respectively. Receiver operating characteristic curve analysis identified a threshold (cutoff) of three bacterial infections at baseline as optimally predictive of severe infections post-SID diagnosis. Multivariate analysis indicated that hospitalizations, infections (≥3), or antibiotic use pre-SID diagnosis were predictive of severe infections post-SID diagnosis. Evaluation of these risk factors could inform clinical decisions regarding which patients may benefit from prophylactic anti-infective treatment, including immunoglobulin replacement if warranted.

Keywords: Secondary infections; hematological malignancies; hypogammaglobulinemia; infection risk factors; secondary immunodeficiency.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Hematologic Neoplasms* / complications
  • Hematologic Neoplasms* / diagnosis
  • Hematologic Neoplasms* / epidemiology
  • Humans
  • Immunoglobulins
  • Immunologic Deficiency Syndromes* / complications
  • Immunologic Deficiency Syndromes* / diagnosis
  • Immunologic Deficiency Syndromes* / epidemiology
  • Retrospective Studies
  • Risk Factors

Substances

  • Immunoglobulins